Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Purchases 10,986 Shares

Posted by Don Miller on May 10th, 2024

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. acquired 10,986 shares of the stock in a transaction that occurred on Wednesday, May 8th. The stock was purchased at an average price of $13.70 per share, for a total transaction of $150,508.20. Following the completion of the acquisition, the insider now owns 3,140,590 shares in the company, valued at approximately $43,026,083. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Monday, May 6th, Saba Capital Management, L.P. purchased 10,713 shares of Abrdn Life Sciences Investors stock. The shares were acquired at an average price of $13.62 per share, with a total value of $145,911.06.
On Thursday, May 2nd, Saba Capital Management, L.P. acquired 26,274 shares of Abrdn Life Sciences Investors stock. The stock was acquired at an average cost of $13.46 per share, with a total value of $353,648.04.
On Tuesday, April 30th, Saba Capital Management, L.P. acquired 16,573 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average cost of $13.13 per share, with a total value of $217,603.49.
On Friday, April 26th, Saba Capital Management, L.P. purchased 120,304 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $13.00 per share, for a total transaction of $1,563,952.00.
On Wednesday, April 24th, Saba Capital Management, L.P. purchased 20,529 shares of Abrdn Life Sciences Investors stock. The shares were acquired at an average price of $13.12 per share, with a total value of $269,340.48.
On Monday, April 22nd, Saba Capital Management, L.P. bought 2,022 shares of Abrdn Life Sciences Investors stock. The shares were acquired at an average price of $12.88 per share, for a total transaction of $26,043.36.
On Thursday, April 18th, Saba Capital Management, L.P. bought 81,738 shares of Abrdn Life Sciences Investors stock. The stock was purchased at an average cost of $12.80 per share, for a total transaction of $1,046,246.40.

Abrdn Life Sciences Investors Stock Performance

Shares of NYSE HQL traded up $0.04 during trading on Friday, reaching $13.86. The company had a trading volume of 38,325 shares, compared to its average volume of 106,519. Abrdn Life Sciences Investors has a twelve month low of $11.34 and a twelve month high of $14.37. The stock has a 50-day moving average price of $13.40 and a two-hundred day moving average price of $13.19.

Institutional Trading of Abrdn Life Sciences Investors

A number of institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its position in shares of Abrdn Life Sciences Investors by 12.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 347,615 shares of the company’s stock worth $4,335,000 after buying an additional 38,000 shares during the last quarter. 180 Wealth Advisors LLC boosted its holdings in Abrdn Life Sciences Investors by 5.3% during the third quarter. 180 Wealth Advisors LLC now owns 114,724 shares of the company’s stock worth $1,431,000 after buying an additional 5,725 shares in the last quarter. Shaker Financial Services LLC raised its holdings in Abrdn Life Sciences Investors by 2.1% during the 3rd quarter. Shaker Financial Services LLC now owns 66,528 shares of the company’s stock worth $830,000 after buying an additional 1,342 shares during the period. Private Advisor Group LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 78.9% in the third quarter. Private Advisor Group LLC now owns 35,046 shares of the company’s stock valued at $435,000 after purchasing an additional 15,459 shares in the last quarter. Finally, RPO LLC boosted its holdings in shares of Abrdn Life Sciences Investors by 75.7% during the third quarter. RPO LLC now owns 327,042 shares of the company’s stock worth $4,078,000 after purchasing an additional 140,942 shares during the period. Hedge funds and other institutional investors own 32.21% of the company’s stock.

About Abrdn Life Sciences Investors

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.